

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



三生制药
3SBIO INC.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1530)

**(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;
(2) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE
DIRECTOR; AND
(3) CHANGE OF COMPOSITION OF THE REMUNERATION
COMMITTEE**

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of 3SBio Inc. (the “**Company**”) announces that with effect from 30 December 2022, Mr. Tang Ke (“**Mr. Tang**”) has resigned as a non-executive Director and a member of the remuneration committee (the “**Remuneration Committee**”) of the Company.

The Board would like to express its gratitude for the contributions of Mr. Tang to the Company during his tenure of service. Mr. Tang has confirmed that he has no disagreement with the Board and there are no matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board further announces that with effect from 30 December 2022, Dr. Zhang Dan (張丹) (“**Dr. Zhang**”) has been appointed as an independent non-executive Director.

The biographical details of Dr. Zhang are set out as follows:

Dr. Zhang Dan (張丹), aged 59, has extensive experience in the field of medicine and pharmaceuticals, and has held numerous respectable and prestigious positions in the industry. Dr. Zhang served as the first chairman of the board of directors (Greater China region) and the Vice-

President of the US company, Quintiles Transnational Corp.. Dr. Zhang had experience working at Sigma Tauresearch Inc., a company established in Italy, during which he was in charge of the clinical development and safety evaluations of drugs in respect of the market in North America. In 2007, Dr. Zhang co-founded ClinChoice Inc. (昆翎醫藥) (formerly known as FMD China (方恩醫藥)), a clinical contract research organization (CRO) dedicated to the development of innovative medicines. He was the chairman of this company from 2007 to 2019, and has been the Chief Strategy Officer and a director of this company since 2020. He has also served as (i) the Chief Scientist at Shenzhen Grandbaybio Development Consulting Co. Limited (深圳興灣生物醫藥發展顧問有限公司) since 2020; (ii) the co-chairman of the board of directors of Hong Ji Biotechnology (Beijing) Co. Limited (弘際生物科技(北京)有限責任公司) since 2021; and (iii) the co-chairman of the board of directors of Jiangsu Hillgene Medical Co. Limited (江蘇譜新生物醫藥有限公司) since 2022.

Dr. Zhang served as a consultant and a visiting professor at Peking Union Medical College and Harbin Medical University, respectively. Dr. Zhang has been a board member of China Pharmaceutical Innovation and Research Development Association (PhIRDA) (中國醫藥創新促進會) from 2020 to 2022. He currently also serves as the head of the ICH E19 IFPMA expert committee and a ICH working group expert in the National Medical Products Administration (國家藥品監督管理局) (NMPA).

Dr. Zhang completed his pre-medical training at the Department of Biology at Peking University in 1984. He then studied Medicine at Peking Union Medical College from 1981 to 1989, and was subsequently awarded with a Doctor of Medicine by the State Council of the PRC government. He further obtained a Master of Public Health degree from Harvard University in 1990 and a Master of Science in Health Care Management degree in 1995 from the Wharton School of the University of Pennsylvania. He was also elected as a foreign member of the Russian Academy of Engineering in 2020.

Dr. Zhang has entered into a letter of appointment with the Company in respect of the appointment as an independent non-executive Director for a term of one year commencing from 30 December 2022. Pursuant to the letter of appointment, Dr. Zhang is entitled to a director's fee of HK\$300,000 per annum, which was determined by the Board on the recommendation of the Remuneration Committee, having considered Dr. Zhang's expected contribution to the Company in terms of time, effort and his expertise, and with reference to the level of remuneration of the other independent non-executive Directors. Pursuant to the second amended and restated articles of association of the Company, Dr. Zhang shall hold office until the next following annual general meeting of the Company following his appointment and shall then be eligible for re-election at the meeting and thereafter, shall be subject to retirement by rotation at the annual general meetings of the Company at least once every three years.

As at the date of this announcement, Dr. Zhang does not have any interests in any shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement, Dr. Zhang (i) does not hold any other positions with the Company or any of its subsidiaries; (ii) save as disclosed in this announcement, he does not

hold any directorship in any other listed public company the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of his appointment, and does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Dr. Zhang has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Save as disclosed above, there are no other matters relating to the appointment of Dr. Zhang that need to be brought to the attention of the Shareholders and there is no other information that should be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to take this opportunity to welcome Dr. Zhang for joining the Board.

CHANGES IN COMPOSITION OF THE REMUNERATION COMMITTEE

In light of the above resignation of non-executive Director and appointment of independent non-executive Director, with effect from 30 December 2022, Dr. Zhang has been appointed as a member of the Remuneration Committee.

By order of the Board
3SBio Inc.
Dr. LOU Jing
Chairman

Hong Kong, 30 December 2022

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin as non-executive Director; and Mr. PU Tianruo, Ms. YANG Hoi Ti Heidi, Mr. Ng, Joo Yeow Gerry and Dr. Zhang Dan as independent non-executive Directors.